



# IDAHO IMMUNIZATION PROGRAM



## 2016-2017 Influenza Vaccine

September 2016

Important information for health care providers enrolled in Idaho Immunization Program (IIP)

### Recommendations

The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for all persons 6 months of age and older, who do not have contraindications, for the prevention and control of seasonal influenza.

Ideally, vaccination should occur before the onset of influenza activity in the community. Health care providers should offer vaccination by the end of October, if possible. Children 6 months through 8 years of age who require 2 doses (see algorithm on page 3) should receive the first dose as soon as possible after the vaccine becomes available. Vaccination should continue to be offered as long as influenza viruses are circulating and unexpired vaccine is available. To avoid missed opportunities for vaccination, providers should offer vaccination to unvaccinated persons during routine health care visits and hospitalizations whenever the vaccine is available.

### 2016-2017 Influenza Vaccine Composition

The U.S. influenza quadrivalent vaccines for 2016-2017 will contain:

- A/California/7/2009 (H1N1)-like virus;
- A/Hong Kong/4801/2014 (H3N2)-like virus;
- B/ Brisbane/60/2008-like virus (Victoria lineage); and
- B/Phuket/3073/2013-like virus (Yamagata lineage).



### Presentations Available from the IIP

<i>TRADE NAME</i>	<i>MANUFACTURER</i>	<i>PRESENTATION</i>	<i>AGE GROUP</i>
Fluzone® - Quadrivalent	Sanofi Pasteur	0.25mL pre-filled syringe	6-35 months
Fluzone® - Quadrivalent	Sanofi Pasteur	0.5mL pre-filled syringe	≥ 36 months
Fluzone® - Quadrivalent	Sanofi Pasteur	0.5mL single dose vial	≥ 36 months
Fluzone® - Quadrivalent	Sanofi Pasteur	5.0mL multi-dose vial	≥ 6 months
Fluarix® - Quadrivalent	GlaxoSmithKline	0.5mL pre-filled syringe	≥ 3 years
FluLaval® - Quadrivalent	GlaxoSmithKline	5.0mL multi-dose vial	≥ 3 years
Flucelvax® - Quadrivalent	Seqirus	0.5mL pre-filled syringe	≥ 4 years

## Supply

Production and distribution of seasonal influenza vaccine is never guaranteed. Each spring the IIP requests, from the Centers for Disease Control and Prevention (CDC), the number of seasonal flu doses needed based on provider surveys, population, estimated vaccine uptake, and available funding. The final number of doses made available to the IIP is dependent upon the contracts CDC secures with vaccine manufacturers, ACIP recommendations, and vaccine production.

This season the ACIP recommended against the use of live-attenuated influenza vaccine (LAIV) based on concerns about effectiveness. LAIV, FluMist<sup>®</sup>, will not be available through the IIP this season. For those providers who requested LAIV on the 2016-2017 Seasonal Influenza Vaccine Survey, inactivated, injectable influenza vaccine (IIV) will be distributed in place of the LAIV.

The requested 2016-2017 seasonal flu vaccine will be allocated by the CDC to the IIP as it becomes available from the distribution center (McKesson) in waves from August through December. The IIP will distribute the influenza vaccine through provider orders as the vaccine is available. While providers can expect to receive the total number of vaccines requested on the 2016-2017 Seasonal Influenza Vaccine Survey, the presentations distributed will vary from the requested presentations due to the replacement of LAIV with IIV.

## Ordering

2016-2017 seasonal influenza vaccine can be ordered from the IIP through the Immunization Reminder Information System (IRIS) beginning September 1, 2016. The available pediatric influenza vaccine will be listed in IRIS on the Create Order screen.

Things to know when ordering seasonal influenza vaccine from the IIP:

- Influenza vaccine orders do not need to follow your organization's ordering frequency.
  - Order influenza vaccine as needed
- Vaccine orders for only influenza will require a current refrigerator temperature and a physical inventory count for influenza vaccine only.
  - All other vaccines ordered must have a complete physical vaccine count submitted. Orders placed without a complete physical vaccine count will be denied.
- Orders may be placed for specific brands and/or presentations; however,
  - If FluMist<sup>®</sup> doses were requested on the 2016-2017 Seasonal Influenza Vaccine Survey, then any 0.5mL presentation may be ordered. The IIP will ship doses based on population served and presentations available.
  - If the brand and/or presentation ordered is not available, then the IIP may choose a substitution for an available presentation.
  - If vaccine is not available, then the order will be denied.
- Orders that are reduced or denied (because the influenza vaccine is not available) will not be tracked and will not be automatically filled at a later date by the IIP. If an influenza order is denied, then a new order will need to be placed by the provider. There will be no backorders.
- On-hand inventory counts will be reviewed during the season as influenza vaccine orders are processed (as with all vaccine orders). Stay current with entering doses of influenza vaccine administered into IRIS.

## Multi-dose Vials (MDV) of Influenza Vaccine

The IIP will be supplying two influenza vaccines in multi-dose vials (MDV). After the MDV vial has been used for the first time the Fluzone® 0.5mL MDV may be used until the expiration date printed on the vial. The FluLaval® 0.5mL MDV may only be administered 28 days after the first use. Please document the "beyond use date" (28 days from the date the MDV of FluLaval® is initially opened) on the label along with the initials of the person noting the date.




## Vaccine Information Sheets

Influenza vaccine information sheets (VIS) are no longer updated every season. The edition dated 8/7/2015 should be used for the 2016-2017 season. Influenza VIS are available to order from the IIP. Please go to the IIP's website at [www.immunizeidaho.com](http://www.immunizeidaho.com) and click on the *Resource Order Form* link on the healthcare provider page or click on the *Related Links* tab in IRIS, then click *Idaho Immunization Program Resource Order Form*.

The current Influenza (Flu) Vaccine (Inactivated or Recombinant) information sheet with an edition date of 8/7/2015 is also available online at <http://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.pdf>

## Dose Recommendations For Children 6 months through 8 years

Influenza vaccine dosing algorithm for children aged 6 months through 8 years for the 2016-2017 influenza season:




\*The two doses need not have been received during the same season or consecutive seasons.

†Doses should be administered at least 4 weeks apart.

Alternate Text: Children aged 6 months through 8 years who have previously received  $\geq 2$  total doses of trivalent or quadrivalent influenza vaccine before July 1, 2016 require only 1 dose for 2016-17. The two previous doses need not have been given during the same season or consecutive seasons. Children in this age group who have not previously received a total of  $\geq 2$  doses of trivalent or quadrivalent influenza vaccine before July 1, 2016 require 2 doses for the 2016-17 season. The interval between the 2 doses should be at least 4 weeks.

For additional information please refer to MMWR / Recommendations and Reports / August 26, 2016 / 65(5);1-54 or visit [https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s\\_cid=rr6505a1\\_w](https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s_cid=rr6505a1_w)

INFLUENZA VACCINE DOSING ALGORITHM  
FOR CHILDREN 6 MONTHS THROUGH 8 YEARS OF AGE  
For the 2016-2017 influenza season



\*The two doses need not have been received during the same season or consecutive seasons.

† Doses should be administered at least 4 weeks apart.

Alternate Text: Children aged 6 months through 8 years who have previously received  $\geq 2$  total doses of trivalent or quadrivalent influenza vaccine before July 1, 2016 require only 1 dose for 2016-17. The two previous doses need not have been given during the same season or consecutive seasons. Children in this age group who have not previously received a total of  $\geq 2$  doses of trivalent or quadrivalent influenza vaccine before July 1, 2016 require 2 doses for the 2016-17 season. The interval between the 2 doses should be at least 4 weeks.

For Additional Information refer to MMWR / Recommendations and Reports / August 26, 2016 / 65(5); 1-54 or visit [https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s\\_cid=rr6505a1\\_w](https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s_cid=rr6505a1_w)

**PEDIATRIC INFLUENZA VACCINE**  
Available from the Idaho Immunization Program  
for the 2016-2017 Season\*

VACCINE	TRADE NAME	MANUFACTURER	PRESENTATION	MERCURY CONTENT (mcg Hg/0.5mL dose)	AGE GROUP	NUMBER OF DOSES	ROUTE	NDC	CPT CODE	CVX CODES (for electronic exports)
IIV4	Fluzone® Quadrivalent	Sanofi Pasteur	0.25mL pre-filled syringe	0	6-35 months	1 or 2	IM**	49281-0516-25	90685	161
			0.5mL pre-filled syringe	0	≥ 36 months	1 or 2	IM**	49281-0416-50	90686	150
			0.5mL single dose vial	0	≥ 36 months	1 or 2	IM**	49281-0416-10	90686	150
			5.0mL multi-dose vial	25	≥ 6 months	1 or 2	IM**	49281-0625-15	90688	158
IIV4	Fluarix® Quadrivalent	GlaxoSmithKline	0.5mL pre-filled syringe	0	≥ 3 years	1 or 2	IM**	58160-0905-52	90686	150
	FluLaval® Quadrivalent		5.0mL multi-dose vial	<25	≥ 3 years	1 or 2	IM**	58160-0903-11	90688	158
IIV4	Flucelvax® Quadrivalent	Seqirus	0.5mL pre-filled syringe	0	≥ 4 years	1 or 2	IM**	70461-0200-01	90674	171

Abbreviations: IIV4=Inactivated Influenza Vaccine, Quadrivalent; IM=intramuscular injection.

\* Immunization providers should check Food and Drug Administration--approved prescribing information for 2016--17 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, and precautions. Package inserts for US-licensed vaccines are available at <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm>

\*\* For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration may be found in the Advisory Committee on Immunization Practices' General Recommendations on Immunization (available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm>).

For additional information regarding 2016-2017 seasonal influenza vaccine please refer to the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report / Recommendations and Reports / August 26, 2016 / 65(5);1-54 or visit [https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s\\_cid=rr6505a1\\_w](https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm?s_cid=rr6505a1_w)

